Hormone Therapy

What is it?
  • Hormone therapy works by depriving cancer cells of the male hormones (androgens) they need to grow.
  • Affects the whole body rather than a particular area.
Most often used to treat:
  • Cancer that has spread outside the prostate
  • Recurrence of prostate cancer after another therapy has been used
  • Men who are at a high risk of experiencing cancer recurrence after surgery or radiation therapy.
What is done?

There are two methods of hormone therapy:

  • Surgical removal of the testicles to prevent testosterone production (rarely used).
  • Medication.
The 2 main categories of medication are:
  • Luteinizing hormone releasing hormone (LHRH) analogues and LHRH agonists, both of which interfere with androgen production.
  • Anti-androgens which block the effects of male hormones on prostate cells.
What to expect?

Hormone therapy is used in various ways to treat prostate cancer.

Combination hormone therapy
Anti-androgens are combined with either LHRH analogue therapy or surgical removal of the testicles.

Intermittent hormone therapy
Hormone therapy is stopped once PSA number is lowered and stabilized. It then resumes when PSA number increases again.

Neoadjuvant hormone therapy
Hormone therapy is given before local treatment. This reduces the size of the tumour to make the “main” treatment potentially more effective.

Adjuvant hormone therapy
Used directly after surgery or radiation to treat cancerous cells that may remain.

Side effects and risks

  • Possible side-effects include:
    • Hot flashes
    • Erectile dysfunction
    • Loss of energy, general weakness
    • Breast enlargement and tenderness
    • Irritability
    • Emotional disturbance including depression
    • Headache
    • Itching, dry skin, rash
    • Gastrointestinal issues: diarrhea, nausea,
    • Vomiting
    • Loss of muscle mass
    • Weight gain (mainly due to increased body fat)
    • Shrinkage of testicles
  • Long-term use may lead to:
    • Osteoporosis
    • Lower blood counts or “anemia”
    • Higher levels of “bad” lipids in the blood
 


Subscribe to our free monthly e-newsletter!

* indicates required

 



PCC Spotlight
New test developed to detect men at high risk of prostate cancer recurrence

Vienna, Austria: A new genetic “signature” to identify prostate cancer patients who are at high risk of their cancer recurring after surgery or radiotherapy has been developed by researchers in Canada, the 33rd conference of the European Society for Radiotherapy and Oncology (ESTRO33) in Vienna will hear today (Saturday). More

CanCertainty for All: Cancer’s Not Fair, But Accessing Treatment Should Be

Toronto, ON – March 10, 2014 – There is no disputing a cancer diagnosis is among the worst news a person or their family could receive. More

$1.8 Million awarded to Movember Rising Stars Supporting Innovators in Prostate Cancer Research

Toronto, ON – February 12, 2014 – Prostate Cancer Canada (PCC) is proud to announce the recipients of its 2014 Movember Rising Star awards in prostate cancer research. More

Support for Those Affected by Prostate Cancer

Toronto, ON - January 28, 2014 – We are pleased to announce a partnership between Prostate Cancer Canada and the Canadian Cancer Society in launching the Prostate Cancer Information Service (PCIS), which provides support to anyone affected by prostate cancer. More


Click here for news archive